This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Aptar Pharma discusses intranasal administration for CNS therapeutics
Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
New solutions for pre-clinical discovery in respiratory healthcare
Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Improving Intranasal Sprays for Respiratory Viral Infections
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions
The Go-To Drug Delivery Expert
Brochures, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Product Solutions
